Sonrotoclax trial in high-risk myelodysplastic syndromes
NCT07885397 tests sonrotoclax in high-risk MDS; ChEMBL potency and 35 ClinicalTrials.gov studies show what is already known about the drug and its target.
Data as of November 6, 2026 · By the BioQ team

The sonrotoclax trial in high-risk myelodysplastic syndromes, NCT07885397, is a PHASE1/PHASE2 study of sonrotoclax plus azacitidine in MDS-IB2. In ChEMBL, BCL2 is the strongest measured target of sonrotoclax, with a best pChEMBL of 10.82 from 5 exact IC50 measurements. ClinicalTrials.gov lists 35 sonrotoclax studies in total. All figures are as of 2026-11-06.
What we asked about the sonrotoclax trial in high-risk myelodysplastic syndromes
NCT07885397 is titled "Sonrotoclax Plus Azacitidine in Patients With MDS-IB2". The sponsor is Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine. The registered condition is Myelodysplastic Syndromes, High Risk, and the phase is PHASE1/PHASE2. The registry record carries a start date in the autumn of 2026.
A trial record tells you what is being tested, not what is known about the drug. So we asked BioQ three things about the intervention:
- Which targets has sonrotoclax been measured against, and how potently?
- Which other trials of sonrotoclax are registered, and in what phases?
- Is there anything in the public layers that places this trial in context?
We ran the single query sonrotoclax. We did not query cancer-model dependency for this note, so it makes no statement about how essential BCL2 is in myelodysplastic or leukemia cell lines.
What BioQ returned for sonrotoclax targets and trials
The first block comes from ChEMBL (compound CHEMBL5314951). It lists 9 targets, 4 of which have exact measurements. The table shows 8. The pChEMBL value is the negative log10 of the molar potency.
| ChEMBL target | Gene | Best pChEMBL | Type | Exact measurements |
|---|---|---|---|---|
| CHEMBL4860 | BCL2 | 10.82 | IC50 | 5 |
| CHEMBL2366159 | — | 9.25 | IC50 | 2 |
| CHEMBL4625 | BCL2L1 | 7.75 | IC50 | 2 |
| CHEMBL614177 | — | 5.6 | IC50 | 1 |
| CHEMBL289 | CYP2D6 | — | — | 0 |
| CHEMBL3356 | CYP1A2 | — | — | 0 |
| CHEMBL3397 | CYP2C9 | — | — | 0 |
| CHEMBL340 | CYP3A4 | — | — | 0 |
BCL2 (CHEMBL4860) leads with a best pChEMBL of 10.82 as an IC50, backed by 5 exact measurements. Next come CHEMBL2366159 at 9.25 (2 measurements) and BCL2L1 at 7.75 (2 measurements). CHEMBL614177 follows at 5.6 with a single measurement. Four cytochrome P450 entries (CYP2D6, CYP1A2, CYP2C9, CYP3A4) are linked to the compound but have no exact potency values. The two targets without a gene symbol in the table are shown by their ChEMBL identifiers only.
The second block comes from ClinicalTrials.gov. It matches 35 studies with sonrotoclax as an intervention: 13 list phase 1, 25 list phase 2 and 5 list phase 3. These counts overlap, because combined PHASE1/PHASE2 studies are counted in both groups. The table is one page of six.
| Trial | Phase | Status | Sponsor | Start | Enrollment |
|---|---|---|---|---|---|
| NCT07887061 | PHASE2 | NOT_YET_RECRUITING | Fred Hutchinson Cancer Center | 2027-01 | 30 |
| NCT04271956 | PHASE2 | RECRUITING | German CLL Study Group | 2020-02 | 83 |
| NCT07799220 | PHASE2 | NOT_YET_RECRUITING | Memorial Sloan Kettering Cancer Center | 2026-09 | 45 |
| NCT04277637 | PHASE1 | ACTIVE_NOT_RECRUITING | BeOne Medicines | 2020-03 | 437 |
| NCT07774234 | PHASE2 | NOT_YET_RECRUITING | The First Affiliated Hospital of Soochow | 2026-08 | 39 |
| NCT06543043 | PHASE1 | COMPLETED | BeiGene | 2024-08 | 30 |
The page shows a spread of sponsors: BeOne Medicines and BeiGene, a cooperative group (German CLL Study Group), and academic centers including Fred Hutchinson Cancer Center, Memorial Sloan Kettering Cancer Center and The First Affiliated Hospital of Soochow. Several entries are not yet recruiting. Enrollment values on this page range from 30 to 437.

What it means and how to read it
The potency data place sonrotoclax among BCL2-family-directed compounds. The best measured value is against BCL2, and the weaker BCL2L1 value is lower on the same pChEMBL scale. That ordering is consistent with a BCL2-focused mechanism of action. It does not by itself prove selectivity in cells, because the values come from different assays and different numbers of measurements. BCL2 has 5 exact measurements, while BCL2L1 has 2.
Read the single-measurement entry (CHEMBL614177, 5.6) with caution. One value cannot show whether the result is reproducible. The CYP rows are a reminder that a ChEMBL link is not a potency. Those four targets are listed with 0 exact measurements, so they say nothing about how strongly the compound acts there.
For the trial, the useful context is that sonrotoclax already has a sizeable registered portfolio. NCT07885397 pairs it with azacitidine in a population defined as high-risk MDS (MDS-IB2). The two other recent entries in the table, from Fred Hutchinson and Memorial Sloan Kettering, are also PHASE2 and not yet recruiting, so this area is only starting to fill in. Whether those studies address the same disease is something to check in the individual records.
Why one query helps: the answer draws on 2 distinct resources, ChEMBL and ClinicalTrials.gov, through 3 engine queries that took 0.31 seconds in total. Doing this by hand means two separate sites, two search syntaxes and a manual match of compound identifiers to target names. Every row above names its source release.
How to reproduce it in BioQ
- Open BioQ and enter the query below exactly as written.
- Open the targets view and sort by best pChEMBL. Check the count of exact measurements next to each value.
- Open the trials view and filter by phase or status. Then open NCT07885397 in the registry to read the arms and eligibility criteria.
- Note the data release shown beside each table, since ChEMBL and ClinicalTrials.gov update on different schedules.
sonrotoclax
Limits: what the data do not show
- The tables describe the drug and the registry, not the outcome of NCT07885397. A newly registered PHASE1/PHASE2 trial has no results, and nothing here supports a statement about benefit, tolerability or dosing.
- pChEMBL values are collected from the literature and mix assay formats. They are not a head-to-head comparison.
- The ChEMBL potency list covers 9 targets. Absence of a target from it means no curated measurement, not no activity.
- The 35-study count reflects the ClinicalTrials.gov snapshot and the intervention name search. Studies registered under other names or elsewhere may be missed.
- Cancer-model dependency data (for example, whether BCL2 matters in particular cell lines) were not part of this query, so this note does not address it.
- Trial status and start dates change. Check the registry record before relying on them.
Data and method
The numbers on this page were read from the BioQ engine on 2026-11-06 (3 queries, 0.3 s of engine time in total). The tables are generated by code from the engine's answers; the text only restates them.
/chembl_potency, /clinicaltrials
Sources
- Sonrotoclax Plus Azacitidine in Patients With MDS-IB2 (2026) — https://clinicaltrials.gov/study/NCT07885397
Run the same query yourself: sonrotoclax
For research use only. This page summarises public data and is not medical advice.
BioQ is an AI search engine and agent with one goal: making biology research 100X faster. Ask in the web app, over the REST API, or from Claude, ChatGPT or Cursor through MCP.
Queries used
Frequently asked questions
What is NCT07885397?
NCT07885397 is a PHASE1/PHASE2 trial titled "Sonrotoclax Plus Azacitidine in Patients With MDS-IB2", sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine. The registered condition is Myelodysplastic Syndromes, High Risk.
What is the strongest measured target of sonrotoclax in ChEMBL?
BCL2 (CHEMBL4860), with a best pChEMBL of 10.82 as an IC50 from 5 exact measurements. BCL2L1 follows at 7.75 from 2 exact measurements.
How many sonrotoclax clinical trials are registered?
ClinicalTrials.gov lists 35 studies with sonrotoclax as an intervention as of 2026-11-06. Of these, 13 list phase 1, 25 list phase 2 and 5 list phase 3, and combined phase studies count in both groups.
How many targets does ChEMBL list for sonrotoclax?
ChEMBL lists 9 targets for sonrotoclax (CHEMBL5314951), and 4 of them have exact potency measurements. The other entries, such as the CYP enzymes, have none.
How long did the BioQ lookup take?
The 3 engine queries took 0.31 seconds in total and drew on 2 distinct resources, ChEMBL and ClinicalTrials.gov.
Sources
- Trial Sonrotoclax Plus Azacitidine in Patients With MDS-IB2 (2026)
- Dataset ClinicalTrials.gov
Results come from public databases as of the date shown and may change. BioQ gives research information, not medical advice.
More from the blog
Tiratricol FDA approval: targets and potency in BioQ
Tiratricol FDA approval (Emcitate): ChEMBL shows 68 targets, THRB and THRA top by pChEMBL, and 3 registered trials on ClinicalTrials.gov, as of 2026-11-17.
Carboplatin Non-Small Cell Lung Cancer trial: NCT07877584
NCT07877584 is a phase 3 NSCLC trial of PD-1 blockade with or without chemotherapy; BioQ adds carboplatin ChEMBL potency and ClinicalTrials.gov context.
Semaglutide new study: what BioQ data show
A new FAERS paper on semaglutide and panic attacks, set against ChEMBL potency, ClinicalTrials.gov registrations and PubChem identity as of 2026-11-15.


